重组抗小鼠TIGIT单抗(10A7) | Syd Labs PA007279.m2a
体内实验级重组抗小鼠TIGIT单抗（克隆号10A7，货号：PA007279.m2a），小鼠IgG2a Kappa 是用哺乳动物细胞生产的重组抗体，可用于ELISA，流式细胞术，中和，功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠TIGIT蛋白影响的生物学途径的测定等研究，纯度: >95%。其不变区为小鼠IgG2a kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007279.m2a |
|---|---|
| 产品名称 | 重组抗小鼠TIGIT单抗(10A7) | Syd Labs PA007279.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody（Clone 10A7）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | VSIG9, VSTM3, WUCAM, T-cell immunoreceptor with Ig and ITIM domains, T cell immunoreceptor with Ig and ITIM domains |
| 概述 | Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 10A7 |
| 同种型 | 小鼠 IgG2a Kappa |
| 免疫源 | 抗小鼠TIGIT单克隆抗体(克隆号: 10A7)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠TIGIT单克隆抗体(克隆号10A7)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存1个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007279.m2a Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠TIGIT蛋白影响的生物学途径的测定。 |
文献
PA007279.m2a: Syd Labs体内实验级重组抗小鼠CD8a单克隆抗体（克隆号2.43），小鼠IgG2a Kappa
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43) 是一种针对小鼠CD8α（Ly-2）链的特异性阻断与耗竭型抗体。CD8作为关键免疫共受体，主要表达于细胞毒性T淋巴细胞（CTL）以及部分树突状细胞（DC）表面，通过识别主要组织相容性复合物Ⅰ类分子（MHC-I），在抗肿瘤细胞毒性免疫、抗病毒感染及同种异体移植排斥反应中发挥核心作用。克隆号2.43抗小鼠CD8a单克隆抗体能特异性结合小鼠CD8α分子，是当前免疫学与肿瘤学研究中用于体内CD8+ T细胞特异性耗竭（in vivo CD8+ T cell depletion）的标准工具抗体。
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43，小鼠IgG2a Kappa) 采用基因工程技术由哺乳动物细胞重组表达，结合小鼠IgG2a Kappa恒定区骨架，有效降低了传统大鼠源抗体在小鼠体内多次给药引发的抗药抗体（ADA）反应。小鼠IgG2a同型骨架具有强大的FcγR结合能力，可通过ADCC（抗体依赖性细胞毒性）及ADCP效应实现高效率、高效价的体内CD8+ T细胞清除。该产品具备超低内毒素、无防腐剂及无载体蛋白等高纯度特性，广泛应用于同系移植肿瘤模型、CD8+ T细胞功能验证、移植免疫耐受及疫苗机制等体内外功能实验。
抗小鼠 TIGIT 单克隆抗体（克隆号：10A7）参考文献：
1. Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Zhang, P., et al. Biomark Res. 2024 Jan 16;12(1):7. PMID: 38229100
“As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion.”
2. Studying TIGIT activity against tumors through the generation of knockout mice
Rishiq, A., et al. Oncoimmunology. 2023 May 29;12(1):2217735. PMID: 37261087
“The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of additional therapies, which are based on other inhibitory receptors. Human TIGIT is an inhibitory receptor expressed by Natural Killer (NK) and T cells and is mainly known to interact with PVR, Nectin-2, Nectin-3, and Nectin-4.”
Zuo, S., et al. EBioMedicine. 2021 Feb:64:103240. PMID: 33581644
“Oncolytic virotherapy with vaccinia virus (VV) can lead to effective anti-tumor immunity by turning “cold” tumors into “hot” tumors. However, its therapeutic potential is affected by the tumor’s local immunosuppressive tumor microenvironment (TME). Therefore, it is necessary to explore the use of immune checkpoint inhibitors to arm oncolytic VVs to enhance their anti-tumor efficacy.”
Waight, A. B., et al. Front Immunol. 2020 Oct 7;11:573405. PMID: 33117369
“The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combination with programmed cell death-1 (PD-1)-directed immune checkpoint blockade, the molecular mechanism behind the observed therapeutic benefits remains poorly understood. Here we demonstrate, using mouse tumor models, that TIGIT blocking antibodies with functional Fc binding potential induce effective anti-tumor response.”
Charpak-Amikam, Y., et al. Nat Commun. 2022 May 5;13(1):2463. PMID: 35513379
“Candida albicans is the most common fungal pathogen and a prevalent cause of deadly bloodstream infections. Better understanding of the immune response against it, and the ways by which it evades immunity, are crucial for developing new therapeutics against it. Natural Killer (NK) cells are innate lymphocytes best known for their role against viruses and tumors.”